# Anthony Stein

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3250660/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 40 papers | 2,136 citations | 567281 15 h-index | 330143 37 g-index |
| 40 all docs | 40 docs citations | 40 times ranked | 3175 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847. | 27.0 | 1,443 |
| 2 | Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews, 2020, 44, 100672. | 5.7 | 135 |
| 3 | Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 618-624. | 2.0 | 84 |
| 4 | Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2665-2673. | 1.3 | 44 |
| 5 | Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1025-1033. | 0.8 | 41 |
| 6 | First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. Journal of Hematology and Oncology, 2018, 11, 61. | 17.0 | 37 |
| 7 | Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. Journal of the American Geriatrics Society, 2019, 67, 978-986. | 2.6 | 36 |
| 8 | Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 301-307. | 2.0 | 35 |
| 9 | Extramedullary Relapse Following Total Marrow and Lymphoid Irradiation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. International Journal of Radiation Oncology Biology Physics, 2014, 89, 75-81. | 0.8 | 30 |
| 10 | Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy. Blood, 2019, 134, 4107-4107. | 1.4 | 23 |
| 11 | Venetoclax-containing regimens in acute myeloid leukemia. Therapeutic Advances in Hematology, 2021, 12, 204062072098664. | 2.5 | 22 |
| 12 | Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. Journal of Medical Economics, 2017, 20, 911-922. | 2.1 | 21 |
| 13 | Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1084-1090. | 2.0 | 19 |
| 14 | CD33 directed bispecific antibodies in acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2020, 33, 101224. | 1.7 | 17 |
| 15 | Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study. Blood, 2019, 134, 4254-4254. | 1.4 | 17 |
| 16 | Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1828-1835. | 2.0 | 15 |
| 17 | Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. Biology of Blood and Marrow Transplantation, 2020, 26, 292-299. | 2.0 | 13 |
| 18 | Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e400-e405. | 0.4 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<scp>HMAâ€Ven</scp>) or liposomal daunorubicinâ€cytarabine (<scp>CPX</scp>â€351). American Journal of Hematology, 2021, 96, E196-E200. | 4.1 | 10 |
| 20 | High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine. Blood, 2019, 134, 2706-2706. | 1.4 | 10 |
| 21 | Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. Leukemia Research, 2019, 87, 106230. | 0.8 | 9 |
| 22 | Exosome-driven lipolysis and bone marrow niche remodeling support leukemia expansion. Haematologica, 2021, 106, 1484-1488. | 3.5 | 9 |
| 23 | Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. Bone Marrow Transplantation, 2021, 56, 2464-2470. | 2.4 | 8 |
| 24 | First Multimodal, Three-Dimensional, Image-Guided Total Marrow Irradiation Model for Preclinical Bone Marrow Transplantation Studies. International Journal of Radiation Oncology Biology Physics, 2021, 111, 671-683. | 0.8 | 8 |
| 25 | Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. Transplantation and Cellular Therapy, 2021, 27, 255.e1-255.e9. | 1.2 | 6 |
| 26 | Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. British Journal of Haematology, 2022, 196, . | 2.5 | 6 |
| 27 | Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1425-1432. | 2.0 | 5 |
| 28 | High prevalence and inferior longâ€term outcomes for <scp>TP53</scp> mutations in therapyâ€related acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, . | 4.1 | 4 |
| 29 | A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease. Leukemia and Lymphoma, 2020, 61, 1052-1062. | 1.3 | 3 |
| 30 | Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. Blood Cancer Journal, 2021, 11, 125. | 6.2 | 2 |
| 31 | Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.. Blood, 2009, 114, 2771-2771. | 1.4 | 2 |
| 32 | Current and Emerging Therapies for Acute Myeloid Leukemia. Cancer Treatment and Research, 2021, 181, 57-73. | 0.5 | 2 |
| 33 | Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplantation, 2021, , . | 2.4 | 2 |
| 34 | Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. Bone Marrow Transplantation, 2022, 57, 830-833. | 2.4 | 2 |
| 35 | Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2022, 63, 1220-1226. | 1.3 | 2 |
| 36 | Rebound thrombocytosis is associated with response in <scp>AML</scp> patients treated with venetoclax and hypomethylating agents. American Journal of Hematology, 2021, 96, E140-E143. | 4.1 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. Blood, 2019, 134, 4518-4518. | 1.4 | 1 |
| 38 | Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.. Blood, 2007, 110, 3021-3021. | 1.4 | 0 |
| 39 | Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in â€œHigh Riskâ€•B-Cell Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 3500-3500. | 1.4 | 0 |
| 40 | 90.y-Ibritumomab Tiuxetan (ZevalinÂ®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).. Blood, 2009, 114, 3357-3357. | 1.4 | 0 |